首页> 美国卫生研究院文献>other >Organometallic Palladium Complexes with a Water-Soluble Iminophosphorane Ligand as Potential Anticancer Agents
【2h】

Organometallic Palladium Complexes with a Water-Soluble Iminophosphorane Ligand as Potential Anticancer Agents

机译:有机金属钯配合物用水溶性硫磷配体作为潜在的抗癌剂

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The synthesis and characterization of a new water-soluble iminophosphorane ligand TPA=N-C(O)-2BrC6H4 (C,N-IM; TPA = 1,3,5-triaza-7-phosphaadamantane) >1 is reported. Oxidative addition of >1 to Pd2(dba)3 affords the orthopalladated dimer [Pd(μ-Br){C6H4(C(O)N=TPA-kC,N)-2}]2 (>2) as a mixture of cis and trans isomers (1:1 molar ratio) where the iminophosphorane moeity behaves as a C,N-pincer ligand. By addition of different neutral or monoanionic ligands to >2, the bridging bromide can be cleaved and a variety of hydrophilic or water-soluble mononuclear organometallic palladium(II) complexes of the type [Pd{C6H4(C(O)N=TPA-kC,N)-2}(L-L)] (L-L = acac (3); S2CNMe2 (>4); 4,7-Diphenyl-1,10-phenanthrolinedisulfonic acid disodium salt C12H6N2(C6H4SO3Na)2 (>5)); [Pd{C6H4(C(O)N=TPA-kC,N)-2}(L)Br] (L = P(mC6H4SO3Na)3 (>6); P(3-Pyridyl)3 (>7)) and, [Pd(C6H4(C(O)N=TPA)-2}(TPA)2Br] (>8) are obtained as single isomers. All new complexes were tested as potential anticancer agents and their cytotoxicity properties were evaluated in vitro against human Jurkat-T acute lymphoblastic leukemia cells, normal T-lymphocytes (PBMC) and DU-145 human prostate cancer cells. Compounds [Pd(μ-Br){C6H4(C(O)N=TPA-kC,N)-2}]2 (>2) and [Pd{C6H4(C(O)N=TPA-kC,N)-2}(acac)] >3 (which has been crystallographically characterized) display the higher cytotoxicity against the above mentioned cancer cell lines while being less toxic to normal T-lymphocytes (peripheral blood mononuclear cells: PBMC). In addition, >3 is very toxic to cisplatin resistant Jurkat shBak indicating a cell death pathway that may be different to that of cisplatin. The interaction of >2 and >3 with plasmid (pBR322) DNA is much weaker than that of cisplatin pointing to an alternative biomolecular target for these cytotoxic compounds. All the compounds show an interaction with human serum albumin (HSA) faster than that of cisplatin.
机译:一种新型的水溶性亚氨基正膦配体TPA = NC(O)-2BrC6H4(C,N-IM; TPA = 1,3,5-triaza-7-phosphaadamantantane)> 1 的合成与表征为报告。将> 1 氧化添加到Pd2(dba)3中可得到原钯酸二聚体[Pd(μ-Br){C6H4(C(O)N = TPA-kC,N)-2}] 2(< (strong> 2 )作为顺式和反式异构体(摩尔比为1:1)的混合物,其中亚氨基膦烷部分起C,N-钳位配体的作用。通过向> 2 中添加不同的中性或单阴离子配体,可以裂解桥联的溴化物,并形成各种类型的[Pd {C6H4(C( O)N = TPA-kC,N)-2}(LL)](LL = acac(3); S2CNMe2(> 4 ); 4,7-二苯基-1,10-菲咯啉二磺酸二钠盐C12H6N2(C6H4SO 3 Na) 2 (> 5 )); [Pd {C 6 H 4 (C(O)N = TPA-kC,N)-2}(L)Br](L = P(mC 6 H 4 SO 3 Na) 3 (> 6 ); P(3-吡啶基) ) 3 (> 7 ))和[Pd(C 6 H 4 (C(O)N = (TPA)-2}(TPA) 2 Br](> 8 )为单一异构体,所有新复合物均作为潜在的抗癌药进行了测试,并评估了它们的细胞毒性。抗人Jurkat-T急性淋巴细胞白血病细胞,正常T淋巴细胞(PBMC)和DU-145人前列腺癌细胞的体外。化合物[Pd(μ-Br){C 6 H 4 (C(O)N = TPA-kC,N)-2}] 2 (> 2 )和[Pd {C 6 H 4 (C(O)N = TPA-kC,N)-2}(acac)] > 3 (已通过晶体学表征)显示出更高的细胞毒性对抗上述癌细胞系,同时对正常T淋巴细胞(外周血单个核细胞:PBMC)的毒性较小。此外,> 3 对顺铂有抗性的Jurkat shBak具有氧化作用,表明其细胞死亡途径可能与顺铂不同。 > 2 和> 3 与质粒(pBR322)DNA的相互作用比顺铂弱得多,这为这些细胞毒性化合物提供了另一种生物分子靶标。与顺铂相比,所有化合物均显示出与人血清白蛋白(HSA)的相互作用更快。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号